Virtue® SAB in the Treatment of Coronary ISR Trial
NCT: NCT07045194 · RECRUITING
NCT IDNCT07045194
StatusRECRUITING
Start Date2025-10-20
Completion2032-10
SponsorOrchestra BioMed, Inc (INDUSTRY)
First posted
Last updated
Brief Summary
A prospective, multi-center, single-blind, randomized (1:1), non-inferiority study comparing clinical outcomes of the Virtue® Sirolimus AngioInfusion™ Balloon (SAB) to the AGENT™ Paclitaxel Drug-Coated Balloon (DCB) in the treatment of coronary artery in-stent restenosis (ISR).
Frequently Asked Questions
What is Virtue® SAB in the Treatment of Coronary ISR Trial?
Virtue® SAB in the Treatment of Coronary ISR Trial is a clinical trial registered under NCT07045194. Current status: RECRUITING.
What is the status of NCT07045194?
The current status of NCT07045194 (Virtue® SAB in the Treatment of Coronary ISR Trial) is: RECRUITING.
When did Virtue® SAB in the Treatment of Coronary ISR Trial start?
Virtue® SAB in the Treatment of Coronary ISR Trial started on 2025-10-20.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.